the two are not mutually exclusive. Though model chemistry resulting in the metal porphyrin mediated ring hydroxylation of aniline has been reported,13 no prior biomimetic work has been carried out in which catalytic N-demethylation has been demonstrated. We are currently exploring the reaction of DMANO with P-450 enzymes.


Acknowledgment. P.S. gratefully thanks the National Institutes of Health for the support as a postdoctoral fellow. This study was supported by grants from the National Institutes of Health and the American Cancer Society.

Asymmetric, Biogenetically Modeled Synthesis of (-)-3-Aminonocardicinic Acid

Craig A. Townsend* and Loan T. Nguyen

Department of Chemistry, The Johns Hopkins University Baltimore, Maryland 21218 Received March 30, 1981

Biosynthetic results obtained in these laboratories support the view that nocardicin A (1) is derived from L-methionine, L-serine, and two units of L-(p-hydroxyphenyl)glycine (Chart I).¹ Incorporation studies with doubly labeled serine have established that β -lactam formation takes place by cyclization of the serve residue without alternation of the oxidation state at the β carbon.¹ If generation of a peptide precursor prior to β -lactam formation is presumed, as is now known² to be the case in penicillin biosynthesis, a direct mechanistic rationale for β -lactam formation is nucleophilic displacement by amide nitrogen of the presumably activated seryl hydroxyl. This proposal is subject to stereochemical and chemical test. In this communication we demonstrate the latter in a biogenetically modeled cyclization of the appropriately protected, optically active dipeptide 2 (Ft = phthalimido) to a 2:1 mixture of 3 and 4, the former being a derivative of (-)-3aminonocardicinic acid (5), the structural element common to all the known nocardicins.³



 Townsend, C. A.; Brown, A. M. J. Am. Chem. Soc. 1981, 103, 2873-4.
 Fawcett, P. A.; Usher, J. J.; Huddleston, J. A.; Bleaney, R. C.; Nisbet, J. J.; Abraham, E. P. Biochem. J. 1976, 157, 651-660. O'Sullivan, J.; Bleaney, R. C.; Huddleston, J. A.; Abraham, E. P. Ibid. 1979, 184, 421-426. Konomi, T.; Herchen, S.; Baldwin, J. E.; Yoshida, M.; Hunt, N. A.; Demain, A. L. Ibid. 1979, 184, 427-430. Sawada, Y.; Baldwin, J. E.; Singh, P. D.; Solomon, N. A.; Demain, A. L. Antimicrob. Agents Chemother. 1980, 18, 465-470. Adriaens, P.; Vanderhaeghe, H. FEMS Microbiol. Lett. 1978, 4 19-21. Meesschaert, B.; Adriaens, P.; Eyssen, H. J. Antibiot. 1980, 33, 722-730.

In considering the possible modes of serine activation in vivo, phosphorylation (or the corresponding pyrophosphate) is at once mechanistically attractive and precedented in L-3-phosphoserine, the immediate precursor of L-serine from the intermediates of glycolysis. Similarly, chemical syntheses of β -lactams involving displacements of primary and secondary halides by amide anions generated typically by sodium hydride in dimethylformamidemethylene chloride had been carried out earlier by Kishi,⁴ Baldwin,⁵ Koppel,⁶ and Wasserman.⁷ However, to more closely mimic the hypothetical in vivo cyclization to the key four-membered ring, a milder reaction system was sought to generate the desired O-phosphorylated intermediate in situ and the necessary amide anion as well, e.g., 7. The Mitsunobu reaction⁸ held promise to fulfill these two requirements. Recently Miller⁹ has reported the conversion of seryl O-alkyl hydroxamates to the corresponding N-oxidized β -lactams using the Mitsunobu reaction. While hydroxamates have biochemical relevance in other contexts, presuming the obligate intermediacy of peptide precursors in penicillin² and nocardicin¹ formation, their direct involvement in β -lactam biosynthesis is uncertain. In the event, we have found that whatever enhancement in acidity of amide hydrogen afforded by oxidation to the corresponding hydroxamate $(pk_a \sim 6-10)$,⁹ it is unnecessary for the sake of cyclization as treatment of serine-containing peptides as 2 under Mitsunobu conditions proceeds rapidly and cleanly at room temperature to yield the corresponding β -lactam to the exclusion of acrylamide or γ -lactam products derived from anion formation at C-3 or C-5, respectively.

The biogenetically modeled synthesis was initially attempted by using the racemic dipeptide 6. N-Phthaloyl-DL-serine¹⁰ was condensed with DL-(p-benzyloxyphenyl)glycine methyl ester in dry dimethylformamide at room temperature with 1.1 equiv of dicyclohexylcarbodiimide and 2.0 equiv of 1-hydroxybenzotriazole hydrate¹¹ to afford 6, after crystallization from ethyl acetatehexanes (83%, mp 126.5-135 °C), as a 10:1 mixture of diastereomers (favoring 2 and its enantiomer) as judged by ¹H NMR spectroscopy at 300 MHz and HPLC analysis. Crystalline 6 was treated under an inert atmosphere with 2.5 equiv each of triphenylphosphine and diethyl diazodicarboxylate in dry tetrahydrofuran at room temperature. After 15 min¹² excess cyclizing reagent was destroyed by addition of water and a mixture of 3a (and enantiomer) and 4a (and enantiomer) was isolated as a viscous oil by chromatography on silica gel (ethyl acetate-hexanes 1:1). Coeluting diethyl hydrazodicarboxylate side product 8 was removed by fractional crystallization from chloroform-hexanes. Hydrogenation at atmospheric pressure (sonication) of the oily mixture of isomers (methanol-acetic acid 1:1) with a 50% weight of 5% palladium on carbon gave a 2:1 mixture of racemic 3b and **4b**, respectively, whose ¹H NMR spectra were identical with published data.¹³ The change in diastereomeric composition in

(3) Hashimoto, M.; Komori, T.; Kamiya, T. J. Am. Chem. Soc. 1976, 98, 3023-3025. J. Antibiot. 1976, 29, 890-901. Hosoda, J.; Konomi, T.; Tani, N.; Aoki, H.; Imanaka, H. Agric. Biol. Chem. 1977, 41, 2013-2020. (4) Nakatsuka, S.; Tanino, H.; Kishi, Y. J. Am. Chem. Soc. 1975, 97, 5008-5010, 5010-5012.

(5) Baldwin, J. E.; Au, A.; Christie, M.; Haber, S. B.; Hesson, D. J. Am. Chem. Soc. 1975, 97, 5957-5958. Baldwin, J. E.; Christie, M. A. Ibid. 1978, 100. 4597-4599

(6) Koppel, G. A.; McShane, L.; Jose, F.; Cooper, R. D. G. Ibid. 1978, 100, 3933-3935

(7) Wasserman, H. H.; Hlasta, D. J. J. Am. Chem. Soc. 1978, 100, 6780-6781. Wasserman, H. H.; Hlasta, D. J.; Tremper, A. W.; Wu, J. S. Tetrahedron Lett. 1979, 549-552. See also: Takahata, H.; Ohnishi, Y.; Yamazaki, T. Heterocycles 1980, 14, 467-469.

(8) Mitsunobu, O.; Wada, M.; Sano, T. J. Am. Chem. Soc. 1972, 94,
(79-680. Wada, M.; Mitsunobu, O. Tetrahedron Lett. 1972, 1279-1282.
Kurihara, T.; Nakajima, Y.; Mitsunobu, O. Ibid. 1976, 2455-2458.
(9) Mattingly, P. G.; Kerwin, Jr., J. F.; Miller, M. J. J. Am. Chem. Soc.
1979, 101, 3983-3985. Miller, M. J.; Mattingly, P. G.; Morrison, M. A.;
Kerwin, I. L. F. Hid 1980, 102, 2022-7032 Kerwin, Jr., J. F. Ibid. 1980, 102, 7026-7032.

(10) Nefkins, G. H. L.; Tesser, G. I.; Nivard, P. J. F. Rec. Trav. Chim. Pays-Bas 1960, 79, 688-698.


(11) König, W.; Geiger, R. Chem. Ber. 1970, 103, 2034-2040.

(12) Monitoring the reaction by thin-layer chromatography (silica gel, ethyl acetate-hexanes 2:1) showed clean conversion of 6 to a single less polar spot.


⁽¹¹⁾ Ziegler, D. M.; Pettit, F. H. Biochem. Biophys. Res. Commun. 1964, 15, 188.

^{(12) (}a) Miwa, G. T.; Garland, W. A.; Hodshon, B. J.; Lu, A. Y. H.; Northrop, D. B. J. Biol. Chem. 1980, 255, 6049. (b) Hlavica, P.; Aichinger, G. Biochim. Biophys. Acta 1978, 544, 185. (c) Hlavica, P.; Kohl, M. Biochem. J. 1977, 164, 487. (d) Willi, P.; Bickel, M. H. Arch. Biochem. Biophys. 1973, 156, 772. (e) Hlavica, P. Biochim. Biophys. Acta 1972, 273, 318.

^{(13) (}a) Sakurai, H.; Shimomura, S.; Fukuzawa, K.; Ishizu, K. Chem. Pharm. Bull. 1978, 26, 1348 and references cited. (b) Adams, P. A.; Berman, M. C.; Baldwin, D. A. J. Chem. Soc., Chem. Commun. 1979, 856.



the course of the cyclization indicated epimerization at one or more of the asymmetric centers. However, the absence of any detectable acrylamide product implied anion formation had not occurred at C-3.



Heartened by the success of the model reaction, we immediately sought to test this approach in an efficient, completely asymmetric synthesis of (-)-3-aminonocardicinic acid (5).^{6,7,13,14} To that end N-phthaloyl-L-serine¹⁵ was condensed with methyl D-(p-benzyloxyphenyl)glycinate¹³ as above to afford 2 as a highly crystalline solid,¹⁶ mp 189–191 °C, $[\alpha]_D = -118^\circ$ (c 1.0, CHCl₃). The optically active peptide was treated under the dehydrating and workup conditions used previously. ¹H NMR analysis of the oily product again showed a 2:1 mixture of diastereomers 3a and 4a. Hydrogenation of this mixture gave 3b and 4b which upon crystallization from absolute ethanol gave pure 3b [43%, mp 169–170 °C, $[\alpha]_D$ –239° (c 0.030, MeOH); lit.¹³ mp 203–204° $[\alpha]_D - 236^\circ$ (c 0.025, MeOH)],¹⁷ establishing, as expected, that the stereochemical integrity of the serine α position remained intact throughout the reaction.¹⁸ The optically pure β -lactam 3b has been sequentially deprotected to (-)-3-aminonocardicinic acid (5) previously,¹³ and hence its obtention constitutes formal completion of the synthesis.

(13) Kamiya, T.; Hashimoto, M.; Nakaguchi, O.; Oku, T. Tetrahedron 1979, 35, 323-328. The cited chemical shift for H-3 in 3b (8 4.89) is in error and should be δ 5.49. This assignment has been kindly confirmed by Dr. M. Hashimoto in a personal communication to Professor M. Koreeda (University of Michigan) whom we thank.

(14) Other approaches to the synthesis of 5: Kamiya, T.; Oku, T.; Nak aguchi, O.; Takeno, H.; Hashimoto, M. Tetrahedron Lett. 1978, 5119-5122. Foglio, M.; Franceschi, G.; Lombardi, P.; Scarfile, C.; Arcamone, F. J. Chem. , Chem. Commun. 1978, 1101-1102. Chiba, K.; Mori, M.; Ban, Y. Ibid. **1980**, 770–772

(15) Hodges, R. S.; Merrifield, R. B. J. Org. Chem. 1974, 39, 1870–1872. (16) Partial NMR (300 MHz, $CDCl_3$) δ 3.70 (s, 3 H, OMe), 4.05–4.13 (4 lines, 1 H, ABX H-4), 4.35–4.41 (4 lines, 1 H, ABX H-4), 4.98–5.02 (4 lines, 1 H, ABX H-3), 5.04 (s, 2 H, OCH_2Ph), 5.51 (d, J = 7 Hz 1 H, H-5), 6.96 (d, J = 8.5 Hz, 2 H, H-8), 7.30 (d, J = 8.5 Hz, 2 H, H-7); IR (CHCl₃) 1780, 1760 (sh), 1720, 1685, 1610, 1510, 1390, 1180 cm⁻¹.

(17) The overall yield of 3b, after drying under high vacuum, is based on the *total* amount of peptide 2 used. The melting point observed in the present work for 3b does not agree with that cited in the literature¹³ and may represent an isomorph. However, with respect to all spectral data and specific rotation, agreement is exact.

(18) Facile base-catalyzed epimerization at C-5 has been observed in 3b¹³ and related esters.⁶

Recognizing the similar acidities of the C-3, C-5, and amide hydrogens, the rapid and highly selective formation of β -lactam in the cyclization reaction is remarkable. Nonetheless, this observation linked with biosynthetic results¹ which show retention of both hydrogens in vivo at the serine β carbon through the course of four-membered-ring formation supports nucleophilic displacement of activated seryl hydroxyl¹⁹ as the key step for β -lactam formation in nocardicin A.

Acknowledgment. We gratefully acknowledge financial support of the National Institutes of Health for the present work (5 R01 AI14937 and 5 S07 RR07041) and providing partial funding to acquire the Bruker WH-300 used (1P41 GM27512).

(19) Triethyl phosphite may be substituted for triphenylphosphine in the in vitro cyclization step with equal success.

Excited-State Energetics and Dynamics of Magnesium Tetraphenylporphyrin Cooled in Supersonic Expansions

Uzi Even,[†] Yaacov Magen,[†] Joshua Jortner,^{*,†} and Haim Levanon[‡]

> Department of Chemistry, Tel Aviv University Ramat Aviv, Tel Aviv and Department of Physical Chemistry The Hebrew University Jerusalem, Israel Received February 18, 1981

The merger between laser technology and supersonic beams¹ led to remarkable progress in spectroscopy of large molecules. Supersonic expansions² provide a source of ultracold "isolated" molecules, characterized by extreme rotational and vibrational cooling.^{1,3,4} Laser spectroscopy of large molecules³⁻¹⁴ seeded in

¹Department of Physical Chemistry, The Hebrew University. (1) (a) Sinha, M. P.; Schultz, A.; Zare, R. N. J. Chem. Phys. **1973**, 58, 549. (b) Smalley, R. E.; Ramakrishna, B. L.; Levy, D. H.; Wharton, L. Ibid., 1974, 61, 4363.

 (3) Levy, D. H.; Warton, L.; Smalley, R. E. "Chemical and Biochemical Applications of Lasers"; Academic Press: New York, 1977; Vol. 2, p 1.
 (4) Levy, D. H.; Wharton, L.; Smalley, R. E. Acc. Chem. Res. 1977, 10, 134

(5) Fitch, P. S. H.; Wharton, L.; Levy D. H. J. Chem. Phys. 1979, 70, 2019

(6) Behlen, F. M.; Mikami, N.; Rice, S. A. Chem. Phys. Lett. 1979, 60, 364

(7) Amirav, A.; Even, U.; Jortner, J. J. Chem. Phys. 1979, 71, 2319.

[†]Department of Chemistry, Tel Aviv University.

⁽²⁾ Kantrovitz, A.; Grey, J. Rev. Sci. Instrum. 1951, 22, 328.